Advice
in the absence of a submission from the holder of the marketing authorisation
apalutamide (Erleada®) is not recommended for use within NHSScotland.
Indication under review: in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice611KB (PDF)
Medicine details
- Medicine name:
- apalutamide (Erleada)
- SMC ID:
- SMC2323
- Indication:
In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 18 January 2021